Table 5_Is takeout culture associated with rising colorectal cancer in young Chinese adults? An ecological analysis of GBD and CHNS data.xlsx by Ling Yao (16961)

“…</p>Results<p>The standardized incidence of Vitamin A deficiency has consistently declined over the past decade. Among non-neoplastic digestive diseases, inflammatory bowel disease showed the most pronounced decrease. …”

Table 1_Is takeout culture associated with rising colorectal cancer in young Chinese adults? An ecological analysis of GBD and CHNS data.docx by Ling Yao (16961)

“…</p>Results<p>The standardized incidence of Vitamin A deficiency has consistently declined over the past decade. Among non-neoplastic digestive diseases, inflammatory bowel disease showed the most pronounced decrease. …”

Supplementary Material for: NANLING: Roxadustat effectiveness/safety in chronic kidney disease-associated anemia with peritoneal dialysis by figshare admin karger (2628495)

“…The change in Total FACT-An score (baseline to Week 24), but not SF-36 scores, was clinically significant (−6.2 [−9.0, −3.4]), with a greater decrease in the T2DM subgroup. …”

Table 2_Is takeout culture associated with rising colorectal cancer in young Chinese adults? An ecological analysis of GBD and CHNS data.xlsx by Ling Yao (16961)

“…</p>Results<p>The standardized incidence of Vitamin A deficiency has consistently declined over the past decade. Among non-neoplastic digestive diseases, inflammatory bowel disease showed the most pronounced decrease. …”

Table 4_Is takeout culture associated with rising colorectal cancer in young Chinese adults? An ecological analysis of GBD and CHNS data.xlsx by Ling Yao (16961)

“…</p>Results<p>The standardized incidence of Vitamin A deficiency has consistently declined over the past decade. Among non-neoplastic digestive diseases, inflammatory bowel disease showed the most pronounced decrease. …”

Table 1_Temporal trends of cervical cancer demographics: a CDC WONDER database study.docx by Grace Folino (21738503)

“…Between 2015 and 2023, there was a concerning positive change in AAMR [APC of 0.1272 (95% CI –0.3393 to 1.7502)], though not statistically significant. Black or African American patients experienced the highest AAMR across races but maintained a decrease in mortality rate over the study period [AAPC of -2.670* (95% CI -2.931 to -2.356)]. …”

Image 4_Temporal trends of cervical cancer demographics: a CDC WONDER database study.png by Grace Folino (21738503)

“…Between 2015 and 2023, there was a concerning positive change in AAMR [APC of 0.1272 (95% CI –0.3393 to 1.7502)], though not statistically significant. Black or African American patients experienced the highest AAMR across races but maintained a decrease in mortality rate over the study period [AAPC of -2.670* (95% CI -2.931 to -2.356)]. …”

Image 2_Temporal trends of cervical cancer demographics: a CDC WONDER database study.png by Grace Folino (21738503)

“…Between 2015 and 2023, there was a concerning positive change in AAMR [APC of 0.1272 (95% CI –0.3393 to 1.7502)], though not statistically significant. Black or African American patients experienced the highest AAMR across races but maintained a decrease in mortality rate over the study period [AAPC of -2.670* (95% CI -2.931 to -2.356)]. …”

Image 3_Temporal trends of cervical cancer demographics: a CDC WONDER database study.png by Grace Folino (21738503)

“…Between 2015 and 2023, there was a concerning positive change in AAMR [APC of 0.1272 (95% CI –0.3393 to 1.7502)], though not statistically significant. Black or African American patients experienced the highest AAMR across races but maintained a decrease in mortality rate over the study period [AAPC of -2.670* (95% CI -2.931 to -2.356)]. …”

Image 5_Temporal trends of cervical cancer demographics: a CDC WONDER database study.png by Grace Folino (21738503)

“…Between 2015 and 2023, there was a concerning positive change in AAMR [APC of 0.1272 (95% CI –0.3393 to 1.7502)], though not statistically significant. Black or African American patients experienced the highest AAMR across races but maintained a decrease in mortality rate over the study period [AAPC of -2.670* (95% CI -2.931 to -2.356)]. …”

Image 1_Temporal trends of cervical cancer demographics: a CDC WONDER database study.png by Grace Folino (21738503)

“…Between 2015 and 2023, there was a concerning positive change in AAMR [APC of 0.1272 (95% CI –0.3393 to 1.7502)], though not statistically significant. Black or African American patients experienced the highest AAMR across races but maintained a decrease in mortality rate over the study period [AAPC of -2.670* (95% CI -2.931 to -2.356)]. …”

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

DataSheet1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.pdf by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”